CERO Secures $350K in Highly Dilutive Convertible Note Financing

summarizeSummary

CERO Therapeutics has issued a highly dilutive convertible note for $350,000, representing over 50% of its market cap, under terms that will likely lead to significant shareholder dilution.

check_boxKey Events

• Secured Convertible Note Financing

  CERO Therapeutics issued and sold a convertible promissory note for a purchase price of $350,000, with a principal face value of $437,500, to Keystone Capital Partners, LLC.

• Highly Dilutive Terms

  The note carries a 10% interest rate and is convertible into common stock at a price that is the lesser of $0.05 or 80% of recent low trading prices, indicating substantial potential dilution for existing shareholders.

• Significant Capital Raise Relative to Market Cap

  The $350,000 raised represents over 50% of the company's current market capitalization, highlighting the significant impact of this financing.

• Follows Prior Disclosure

  The terms of this convertible note were previously disclosed in an 8-K filing on February 13, 2026, with this filing confirming the actual issuance and sale of the note.

auto_awesomeAnalysis

This 8-K reports that CERO Therapeutics Holdings, Inc. has issued and sold a convertible promissory note for $350,000, with a principal face value of $437,500, to Keystone Capital Partners, LLC. While the terms of this note were previously disclosed on February 13, 2026, this filing confirms the actual drawdown of capital. The financing is highly dilutive, as the $350,000 raised represents over 50% of the company's current market capitalization. The note bears 10% interest and is convertible at a price that is the lesser of $0.05 or 80% of recent low trading prices, which will likely result in significant share issuance at a deep discount to the current stock price, especially given the company is trading near its 52-week low. This type of financing often signals financial distress and creates substantial overhang for existing shareholders.